TTRA Information Session: Funding call for Drugs and Devices Addressing Cardiovascular Disease and Complications of Diabetes
Description
In July 2024, MTPConnect was selected to deliver a new $28.5 million investment for Drugs and Devices, which builds on the legacy of the inaugural TTRA program.
The objective of TTRA Drugs and Devices is to accelerate development and commercialisation of promising drugs and medical devices into products that can reduce the burden of cardiovascular disease and complications of diabetes for patients, carers, families and community.
TTRA Drugs and Devices is now calling for Expressions of Interest (EOI), to fund eligible Australian start-ups, spin-outs and SMEs to develop innovative preventative, diagnostic, therapeutic and/or disease management drugs and devices for cardiovascular disease and the complications of diabetes (type 1 and type 2). Guidelines & application information can be found on the TTRA webpage. Submissions close at 16:00 AEDT on Monday 4 November 2024.
Hear from MTPConnect's TTRA Team Lauren Kelly, Dr Mana Liao and Dr Erin McAllum as well as experts Kenny Lean from Roche Diagnostics Australia, Dr Perdita Cheshire from CSL and Renza Scibilia from Breakthrough T1D.
See the TTRA Drugs and Devices webpage for more information.
United States
